Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.230
Neutral
RSI(14)
68.739
Neutral
STOCH(KDJ)(9,3,3)
45.805
Neutral
ATR(14)
0.511
Low Volatility
CCI(14)
91.225
Neutral
Williams %R
46.774
Neutral
TRIX(12,20)
4.180
Sell
StochRSI(14)
100.000
Buy
Search
Curis Inc
CRISAdd to Watchlist
5.033USD
+0.073+1.47%
Close 07-31 16:00（ET）Quotes delayed by 15 min
10.06MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.47%
5 Days
+2.92%
1 Month
+863.93%
6 Months
+460.43%
Year to Date
+409.85%
1 Year
+203.17%
Key Figures
5.000Open
5.173High
14.71KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.74%Turnover Ratio
4.960Prev. Close
4.918Low
67.66KTurnover
LossP/E Static
0.79P/B
0.00%Div Yield TTM
-61.34%ROA
3.13052wk High
0.18Volume Ratio
-43.39MNet Profit
2.00MShares
-0.5758EPS TTM
3.03Beta
-693.93%ROE
0.46452wk Low
5.14%Amplitude
76.38%Gross Margin
10.06MMarket Cap
184.68Reward/Risk
7.21%Risk Rate
TradingKey Stock Score of Curis Inc
Currency: USD Updated: 2026-07-31Key Insights
Curis Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 114 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 280.00.In the medium term, the stock price is expected to trend up.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Curis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Curis Inc Highlights
StrengthsRisks
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.44M.
Undervalued
The company’s latest PE is -8.72, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.82M shares, increasing 31.37% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 51.34K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.79.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
280.000
Target Price
+5522.49%
Upside Space
Curis Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
4
analysts
Buy
Current Rating
280.000
Target Price
+5522.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Curis Inc
CRIS
4
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
4.896
Buy
MA10
4.825
Buy
MA20
4.904
Buy
MA50
2.228
Buy
MA100
1.431
Buy
MA200
1.295
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Curis Inc Info
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Ticker SymbolCRIS
CompanyCuris Inc
CEODentzer (James E)
Websitehttps://www.curis.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Curis Inc (CRIS)?
The current price of Curis Inc (CRIS) is 5.03.
What is the symbol of Curis Inc?
The ticker symbol of Curis Inc is CRIS.
What is the 52-week high of Curis Inc?
The 52-week high of Curis Inc is 3.13.
What is the 52-week low of Curis Inc?
The 52-week low of Curis Inc is 0.46.
What is the market capitalization of Curis Inc?
The market capitalization of Curis Inc is 10.06M.
Is Curis Inc (CRIS) currently rated as Buy, Hold, or Sell?
According to analysts, Curis Inc (CRIS) has an overall rating of Buy, with a price target of 280.00.
What is the Earnings Per Share (EPS TTM) of Curis Inc (CRIS)?
The Earnings Per Share (EPS TTM) of Curis Inc (CRIS) is -11.52.